Assessing Psoriasis Severity and Outcomes for Clinical Trials and Routine Clinical Practice

Dermatologic Clinics

Volumn 33, Issue 1, 2015, Pages 57-71

  Chalmers, Robert J G ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

COSMIN; Outcome measures; PROM; Psoriasis; Psychosocial morbidity; Quality of life; Self assessment; Severity assessment

Indexed keywords

ANTIPSORIASIS AGENT; CORTICOSTEROID; CYCLOSPORIN; DITHRANOL; ETRETINATE; FUMARIC ACID ESTER DERIVATIVE; PSORALEN; RETINOID; TAR; UNCLASSIFIED DRUG;

CLINICAL ASSESSMENT TOOL; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); CONSTRUCT VALIDITY; CONTENT VALIDITY; CRITERION RELATED VALIDITY; DERMATOLOGY LIFE QUALITY INDEX; DISEASE ASSOCIATION; DISEASE CLEARANCE; DISEASE SEVERITY; DISTRESS SYNDROME; FACE VALIDITY; HEALTH CARE COST; HUMAN; INTERRATER RELIABILITY; INTRARATER RELIABILITY; LATTICE SYSTEM PHYSICIAN GLOBAL ASSESSMENT; MENTAL HEALTH; MINIMAL RESIDUAL DISEASE; OUTCOME ASSESSMENT; PHOTOCHEMOTHERAPY; PHOTOTHERAPY; PHYSICIAN GLOBAL ASSESSMENT; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS AREA AND SEVERITY INDEX 75; PSORIASIS AREA AND SEVERITY INDEX 90; PSYCHOLOGICAL WELL BEING; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SELF EVALUATION; SHORT FORM 36; SIMPLIFIED PSORIASIS INDEX; TEST RETEST RELIABILITY; ULTRAVIOLET B RADIATION; OBSERVER VARIATION; PATHOLOGY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

CLINICAL TRIALS AS TOPIC; DIAGNOSTIC SELF EVALUATION; HUMANS; OBSERVER VARIATION; PSORIASIS; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84911468025     PISSN: 07338635     EISSN: 15580520     Source Type: Journal    
DOI: 10.1016/j.det.2014.09.005     Document Type: Review

References (50)

1. UK National Clinical Guideline Centre (2012). Psoriasis: assessment and management of psoriasis. Available at: . Accessed May 22, 2014. http://www.nice.org.uk/nicemedia/live/13938/61192/61192.pdf.
2. Kragballe K., Gniadecki R., Mørk N.J., et al. Implementing best practice in psoriasis: a Nordic expert group consensus. Acta Dermatovenerol 2014, 94:547-552. 10.2340/00015555-1809.
3. Pathirana D., Ormerod A.D., Saiag P., et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. JEur Acad Dermatol Venereol 2009, 23(Suppl 2):1-70.
4. Fredriksson T., Pettersson U. Severe psoriasis-oral therapy with a new retinoid. Dermatologica 1978, 157:238-244.
5. NHS England. Patient Reported Outcome Measures (PROMs). Available at: . Accessed May 22, 2014. http://www.england.nhs.uk/statistics/statistical-work-areas/proms/.
6. US Food and Drug Administration. Patient-reported outcome measures: use in medical product development to support labeling claims. Guidance for industry. 2009. Available at: . Accessed May 29, 2014. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM071975.pdf.
7. UK National Institute for Health and Care Excellence (2012). PH38 preventing type 2 diabetes: risk identification and interventions for individuals at high risk. Available at: . Accessed May 29, 2014. http://publications.nice.org.uk/preventing-type-2-diabetes-risk-identification-and-interventions-for-individuals-at-high-risk-ph38/.
8. Fava G.A., Tomba E., Sonino N. Clinimetrics: the science of clinical measurements. Int J Clin Pract 2012, 6:11-15.
9. Heydendael V., Spuls P.I., Opmeer B., et al. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. NEngl J Med 2003, 349:658-665.
10. Khoo O.T., Fung W.P., Koh K.Y. Clinical trial of P-1742 topical or fluperolone (9 fluoro-21 methyl prednisolone) in psoriasis. Singapore Med J 1964, 5:69-72.
11. Parrish J.A., Fitzpatrick T.B., Tanenbaum L., et al. Photochemotherapy of psoriasis with oral methoxsalen and longwave ultraviolet light. NEngl J Med 1974, 291:1207-1211.
12. Rogers S., Marks J., Shuster S., et al. Comparison of photochemotherapy and dithranol in the treatment of chronic plaque psoriasis. Lancet 1979, 8114:455-458.
13. Yones S.S., Palmer M.A., Garibaldinos T.T., et al. Randomized double-blind trial of the treatment of chronic plaque psoriasis: efficacy of psoralen-UV-A therapy vs narrowband UV-B therapy. Arch Dermatol 2006, 142:836-842.
14. UK National Institute for Health and Care Excellence. Psoriasis: management of psoriasis - tools for assessing disease severity and impact. Available at: . Accessed May 24, 2014. http://www.nice.org.uk/nicemedia/live/12344/58871/58871.pdf.
15. Naldi L., Svensson A., Diepgen T., et al. Randomized clinical trials for psoriasis 1977-2000: the EDEN survey. JInvest Dermatol 2003, 120:738-741.
16. Griffiths C.E., Clark C.M., Chalmers R.J., et al. Asystematic review of treatments for severe psoriasis. Health Technol Assess 2000, 4(40):1-125.
17. European Medicines Agency. Guideline on clinical investigation of medicinal products indicated for the treatment of psoriasis. 2004. Available at: . Accessed May 30, 2014. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003329.pdf.
18. UK National Institute for Health and Care Excellence. Psoriasis - assessment and management of psoriasis - clinical guideline - methods, evidence and recommendations. 2012. Available at: . Accessed May 30, 2014. http://www.nice.org.uk/nicemedia/live/13938/61192/61192.pdf.
19. Robinson A., Kardos M., Kimball A.B. Physician Global Assessment (PGA) and Psoriasis Area and Severity Index (PASI): why do both? A systematic analysis of randomized controlled trials of biologic agents for moderate to severe plaque psoriasis. JAm Acad Dermatol 2012, 66:369-375.
20. Fleischer A.B., Rapp S.R., Reboussin D.M., et al. Patient measurement of psoriasis disease severity with a structured instrument. JInvest Dermatol 1994, 102:967-969.
21. Feldman S.R., Fleischer A.B., Reboussin D.M., et al. The self-administered psoriasis area and severity index is valid and reliable. JInvest Dermatol 1996, 106:183-186.
22. Chularojanamontri L., Griffiths C.E., Chalmers R.J. The Simplified Psoriasis Index (SPI): a practical tool for assessing psoriasis. JInvest Dermatol 2013, 133:1956-1962.
23. Chularojanamontri L., Griffiths C.E., Chalmers R.J. Responsiveness to change and interpretability of the simplified psoriasis index. JInvest Dermatol 2014, 134:351-358.
24. Wittkower E. Psychological aspects of psoriasis. Lancet 1946, 1:566-569.
25. Seville R.H. Psoriasis and stress. Br J Dermatol 1977, 97:297-302.
26. Jobling R. Psoriasis-a preliminary questionnaire study of sufferers' subjective experience. Clin Exp Dermatol 1976, 1:233-236.
27. International Society for Quality of Life Research. About ISOQOL. Available at: . Accessed May 31, 2014. http://www.isoqol.org/about-isoqol.
28. Ware J., Sherbourne C.D. The MOS 36-item short-form health survey (SF-36): I. Conceptual framework and item selection. Med Care 1992, 30:473-483.
29. Finlay A.Y., Kelly S.E. Psoriasis - an index of disability. Clin Exp Dermatol 1987, 12:8-11.
30. Lewis V.J., Finlay A.Y. Two decades' experience of the psoriasis disability index. Dermatology 2005, 210:261-268.
31. Finlay A.Y., Khan G.K. Dermatology Life quality Index (DLQI): a simple practical measure for routine clinical use. Clin Exp Dermatol 1994, 19:210-216.
32. Finlay A.Y. Current severe psoriasis and the Rule of Tens. Br J Dermatol 2005, 152:861-867.
33. Smith C.H., Anstey A.V., Barker J.N., et al. British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009. Br J Dermatol 2009, 161:987-1019.
34. Baker C., Mack A., Cooper A., et al. Treatment goals for moderate to severe psoriasis: an Australian consensus. Australas J Dermatol 2013, 54:148-154.
35. Boehncke W.H., Brasie R.A., Barker J., et al. Recommendations for the use of etanercept in psoriasis: a European dermatology expert group consensus. JEur Acad Dermatol Venereol 2006, 20:988-998.
36. Feinstein A.R. Clinimetrics 1987, Yale University Press, New Haven (CT).
37. COSMIN. COnsensus-based Standards for the selection of health Measurement Instruments. Available at: . Accessed May 31, 2014. http://www.cosmin.nl/cosmin_1_0.html.
38. Ramsay B., Lawrence C.M. Measurement of involved surface area in patients with psoriasis. Br J Dermatol 1991, 124:565-570.
39. Marks R., Barton S.P., Shuttleworth D. Assessment of disease progress in psoriasis. Arch Dermatol 1989, 125:235-240.
40. Feldman S.R. Aquantitative definition of severe psoriasis for use in clinical trials. JDermatolog Treat 2004, 15:27-29.
41. Jacobson C.C., Kimball A.B. Rethinking the psoriasis area and severity index: the impact of area should be increased. Br J Dermatol 2004, 151:381-387.
42. Louden B.A., Pearce D.J., Lang W., et al. ASimplified Psoriasis Area Severity Index (SPASI) for rating psoriasis severity in clinic patients. Dermatol Online J 2004, 10:7.
43. Henseler T., Schmitt-Rau K.A. Acomparison between BSA, PASI, PLASI and SAPASI as measures of disease severity and improvement by therapy in patients with psoriasis. Int J Dermatol 2008, 47:1019-1023.
44. Feldman S.R., Krueger G.G. Psoriasis assessment tools in clinical trials. Ann Rheum Dis 2005, 64:ii65-ii68.
45. Langley R.G., Ellis C.N. Evaluating psoriasis with psoriasis area and severity index, psoriasis global assessment, and lattice system physician's global assessment. JAm Acad Dermatol 2004, 51:563-569.
46. Walsh J.A., McFadden M., Woodcock J., et al. Product of the physician global assessment and body surface area: a simple static measure of psoriasis severity in a longitudinal cohort. JAm Acad Dermatol 2013, 69:931-937.
47. Bronsard V., Paul C., Prey S., et al. What are the best outcome measures for assessing quality of life in plaque type psoriasis? a systematic review of the literature. JEur Acad Dermatol Venereol 2010, 24:17-22.
48. Pincus T., Strand V., Koch G., et al. An index of the three core data set patient questionnaire measures distinguishes efficacy of active treatment from that of placebo as effectively as the American College of Rheumatology 20% response criteria (ACR20) or the Disease Activity Score (DAS) in a rheumatoid arthritis clinical trial. Arthritis Rheum 2003, 48:625-630.
49. Kirby B., Fortune D.G., Bhushan M., et al. The Salford Psoriasis Index: an holistic measure of psoriasis severity. Br J Dermatol 2000, 142:728-732.
50. Puig L. Shortcomings of PASI75 and practical calculation of PASI area component. JAm Acad Dermatol 2013, 68:180-181.